Review
Open access
Oct 2026
Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity
Pleural mesothelioma (PM) is a rare and aggressive cancer with limited treatment options and poor prognosis. Unlike other thoracic cancers responding well to immunotherapy, PM typically lacks key predictive biomarkers such as Programmed Death-Ligand 1 (PD-L1) tumor expression. Nonetheless, immune checkpoint inhibitors...
L. Cerbone, Alessia Garau, Andrea Balossino et al.
· Frontiers in Immunology · 0 citations